Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients
Cancer · 15.08.2026 · 132 (16)
DOI: 10.1002/cncr.70562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 07.08.2026. Verfasst von Liuye Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Diphosphonates, Triple Negative Breast Neoplasms, Neoplasm Recurrence, Local, Bone Density Conservation Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Breast Cancer Research Foundation, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Bisphosphonates (BPs) are routinely used as an adjuvant therapy for breast cancer to reduce the risk of bone recurrences given their anti‐resorptive effects on bones and antitumor characteristics. However, there remains limited evidence regarding their utility across different subtypes.
Methods
In this population‐based cohort study, the authors assessed the effects of pre‐ and post‐diagnostic BP use on recurrence, any second breast cancer event, all‐cause mortality (ACM), and breast cancer–specific mortality (BCSM) using multivariable‐adjusted Cox proportional hazards models among hormone receptor–positive (HR+) and triple‐negative breast cancer (TNBC) participants.
Results
This study enrolled 2260 HR+ and 1436 TNBC participants. The median age and follow‐up time to death was 51 and 52 years old and 168.3 and 147 months in the two subtypes, respectively. Post‐diagnostic BP use for at least 1 year was protective for ACM (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.49–0.93) and BCSM (HR, 0.54; 95% CI, 0.33–0.89) compared to never users in HR+ cases. Among participants who initiated BP after diagnosis only, a lower point estimates on the clinical outcomes were observed across both subtypes, reaching statistical significance for BCSM (HR, 0.62; 95% CI, 0.39–0.98) in HR+ cases. Among TNBC cases who continued BP use post‐diagnosis, increased risks of recurrence (HR, 3.43; 95% CI, 1.67–7.07) and BCSM (HR, 2.54; 95% CI, 1.24–5.19) were observed.
Conclusions
Although this study confirmed the protective effects of post‐diagnostic BP use on risks of mortality among HR+ cases, further studies are required to prove the effects of post‐diagnostic BP use among TNBC participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Epidemiology, University of Washington, Seattle, Washington, USA.
- Department of Epidemiology, University of Colorado-Anschutz, Aurora, Colorado, USA.
- Department of Biostatistics, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Liuye Huang, Christopher I Li
Förderung
- Breast Cancer Research Foundation
- NCI NIH HHS
Zitieren
APA
Huang, L., Cook, L. S., Tang, M. C., Doody, D. R., Peters, U., Sun, W., Huyghe, J. R., Malone, K. E., & Li, C. I. (2026). Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients. Cancer, 132(16). https://doi.org/10.1002/cncr.70562
Vancouver
Huang L, Cook LS, Tang MC, Doody DR, Peters U, Sun W, et al. Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients. Cancer. 2026;132(16). doi:10.1002/cncr.70562
BibTeX
@article{Huang2026,
author = {Huang, Liuye and Cook, Linda S and Tang, Mei-Tzu C and Doody, David R and Peters, Ulrike and Sun, Wei and Huyghe, Jeroen R and Malone, Kathleen E and Li, Christopher I},
title = {Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients},
journal = {Cancer},
year = {2026},
volume = {132},
number = {16},
doi = {10.1002/cncr.70562}
}
EUVIMED